IL17RA and hepatocellular carcinoma: However, recent studies indicated that mice devoid of IL-17RA in steatotic hepatocytes were protected from non-alcoholic steatohepatitis (NASH)- and ALD-induced HCC due to reduced inflammatory responses and suppression of cholesterol and fatty acid synthesis in steatotic hepatocytes (37), suggesting that IL-17RA signaling in steatotic hepatocytes is critical for the pathogenesis of NASH- and ALD-induced HCC and IL-17RA targeting therapies are likely to has the potential for the suppression of pathogenic inflammation.